BACKGROUND: Optimal treatment regimens for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are not well-defined. OBJECTIVES: This study describes the treatment and outcomes in patients with urinary tract infection (UTI) caused by KPC-producing Enterobacteriaceae. METHODS: This retrospective cohort study analyzed data from adult inpatients with bacteriuria caused by KPC-positive organisms treated at Barnes-Jewish Hospital from June 1, 2006, to February 1, 2008. KPC-positive isolates were identified utilizing disk-diffusion susceptibility testing and confirmed to contain bla(KPC) via molecular methods. RESULTS: Twenty-one patients met the inclusion criteria and all were classified as having symptomatic UTI. The majority of patients were female (15/21 [71%]), and the mean (SD) age was 62.4 (15.2) years. Successful clinical and microbiologic responses were observed in 16 patients (76%) for both outcomes. Patients with urinary catheters had them removed or replaced in 9 of 15 cases (60%). Antibiotics active against the isolated pathogen were provided in 14 of 21 cases (67%), often after considerable delay (median, 72.5 hours [range, 4-312 hours]). All 7 patients receiving aminoglycoside therapy had successful clinical and microbiologic responses, and in vitro testing of an extended antibiotic panel revealed high susceptibility rates for tigecycline (28/29 [97%]), minocycline (22/29 [76%]), and fosfomycin (25/29 [86%]) against the KPC-positive isolates. CONCLUSIONS: Although receipt of appropriate therapy was delayed in many cases, clinical outcomes investigated revealed [corrected] high rates of successful response in this defined group of patients Aminoglycosides and tetracycline derivatives suggested therapeutic promise in the treatment of KPC-producing Enterobacteriaceae UTI.
BACKGROUND: Optimal treatment regimens for infections caused by Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae are not well-defined. OBJECTIVES: This study describes the treatment and outcomes in patients with urinary tract infection (UTI) caused by KPC-producing Enterobacteriaceae. METHODS: This retrospective cohort study analyzed data from adult inpatients with bacteriuria caused by KPC-positive organisms treated at Barnes-Jewish Hospital from June 1, 2006, to February 1, 2008. KPC-positive isolates were identified utilizing disk-diffusion susceptibility testing and confirmed to contain bla(KPC) via molecular methods. RESULTS: Twenty-one patients met the inclusion criteria and all were classified as having symptomatic UTI. The majority of patients were female (15/21 [71%]), and the mean (SD) age was 62.4 (15.2) years. Successful clinical and microbiologic responses were observed in 16 patients (76%) for both outcomes. Patients with urinary catheters had them removed or replaced in 9 of 15 cases (60%). Antibiotics active against the isolated pathogen were provided in 14 of 21 cases (67%), often after considerable delay (median, 72.5 hours [range, 4-312 hours]). All 7 patients receiving aminoglycoside therapy had successful clinical and microbiologic responses, and in vitro testing of an extended antibiotic panel revealed high susceptibility rates for tigecycline (28/29 [97%]), minocycline (22/29 [76%]), and fosfomycin (25/29 [86%]) against the KPC-positive isolates. CONCLUSIONS: Although receipt of appropriate therapy was delayed in many cases, clinical outcomes investigated revealed [corrected] high rates of successful response in this defined group of patientsAminoglycosides and tetracycline derivatives suggested therapeutic promise in the treatment of KPC-producing Enterobacteriaceae UTI.
Authors: Robert S Liao; Gregory A Storch; Richard S Buller; Rachel C Orscheln; Elaine R Mardis; Jon R Armstrong; W Michael Dunne Journal: J Clin Microbiol Date: 2006-06 Impact factor: 5.948
Authors: Jonas Marschall; Robert J Tibbetts; W Michael Dunne; Jonathan G Frye; Victoria J Fraser; David K Warren Journal: J Clin Microbiol Date: 2008-11-19 Impact factor: 5.948
Authors: Helen W Boucher; George H Talbot; John S Bradley; John E Edwards; David Gilbert; Louis B Rice; Michael Scheld; Brad Spellberg; John Bartlett Journal: Clin Infect Dis Date: 2009-01-01 Impact factor: 9.079
Authors: Andrea Endimiani; Lenore L Carias; Andrea M Hujer; Christopher R Bethel; Kristine M Hujer; Federico Perez; Rebecca A Hutton; William R Fox; Geraldine S Hall; Michael R Jacobs; David L Paterson; Louis B Rice; Stephen G Jenkins; Fred C Tenover; Robert A Bonomo Journal: Antimicrob Agents Chemother Date: 2008-04-21 Impact factor: 5.191
Authors: Lalitagauri M Deshpande; Paul R Rhomberg; Helio S Sader; Ronald N Jones Journal: Diagn Microbiol Infect Dis Date: 2006-10-03 Impact factor: 2.803
Authors: V G Del Vecchio; J M Petroziello; M J Gress; F K McCleskey; G P Melcher; H K Crouch; J R Lupski Journal: J Clin Microbiol Date: 1995-08 Impact factor: 5.948
Authors: Gopi Patel; Shirish Huprikar; Stephanie H Factor; Stephen G Jenkins; David P Calfee Journal: Infect Control Hosp Epidemiol Date: 2008-12 Impact factor: 3.254
Authors: David van Duin; Eric Cober; Sandra S Richter; Federico Perez; Robert C Kalayjian; Robert A Salata; Scott Evans; Vance G Fowler; Keith S Kaye; Robert A Bonomo Journal: J Antimicrob Chemother Date: 2014-12-09 Impact factor: 5.790